Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
  • A61K47/38—Cellulose; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
  • A61K9/7007—Drug-containing films, membranes or sheets
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants

Definitions

• the present invention relates to an oral thin film, a process for its production and its use as a medicament.
• Mouth mucosa are created and dissolve there. These are, in particular, thin active substance-containing films based on polymers which, when applied to a mucous membrane, in particular the oral mucosa, release the active ingredient directly into the latter.
• Oral mucosa ensures a rapid transfer of the drug into the bloodstream.
• This delivery system has the advantage that the active ingredient is largely absorbed through the mucous membrane and thus avoids the "first-pass metabolism" which occurs in the conventional dosage form of a drug in tablet form
• the drug can be dissolved, emulsified or dispersed in the film become.
• Oral thin films known in the art have the disadvantage that the larger the disintegration time of oral thin films
• Basis weight and thus the active substance content of the oral thin film is. Depending on the application, however, long disintegration times are undesirable.
• known oral thin films have the disadvantage that the maximum basis weight and thus the amount of pharmaceutically active ingredient contained is determined by the drying of the oral thin film at its Fier ein. Although, the larger the basis weight of the oral thin film, the more pharmaceutically active ingredient may be contained therein, the drying time of the oral thin film is prolonged to a no longer economical time, and in addition, inhomogeneous distribution of the active ingredient in the oral thin film may occur ,
• the object of the present invention is to overcome the above-mentioned disadvantages of the prior art.
• the object of the present invention is to provide an oral thin film having a relatively high active ingredient content, i. an active ingredient content of at least about 20% by weight, based on the total weight of the oral thin film, having a relatively short disintegration time, and wherein the pharmaceutically active agent is relatively homogeneously distributed in the oral thin film.
• another object of the present invention is to provide an economically acceptable
• an oral thin film according to claim 1 comprising at least one cellulose derivative and at least one pharmaceutically active ingredient, and characterized in that the at least one pharmaceutically active ingredient has a water solubility of at most about 50 g / L at 20 ° C and a pFH of 6 to 7 and in an amount of at least about 20% by weight, based on the total weight of the oral thin film, in the oral thin film.
• the water solubility of the at least one pharmaceutically active ingredient is at most about 50 g / L at 20 ° C and a pFH of 6 to 7.
• the oral thin film according to the invention is characterized by a relatively high loading of the at least one pharmaceutically active ingredient.
• the amount of the at least one pharmaceutically active ingredient is at least about 20% by weight, preferably at least about 30% by weight, more preferably at least about 35% by weight and most preferably at least about 40% by weight, based on the Total weight of the oral
• cellulose derivative any natural or synthetic polymer which is derived from cellulose or which can be obtained by modification of cellulose. Possible modifications include methylation,
• the oral thin film according to the invention is preferably characterized in that the at least one cellulose derivative is present in an amount of about 5 to 80 wt.%, Preferably of about 10 to 70 wt.%, Particularly preferably of about 20 to 60 wt. based on the total weight of the oral thin film contained in the oral thin film.
• the oral thin film according to the invention is characterized in that the at least one cellulose derivative comprises a water-soluble and / or water-swellable cellulose derivative.
• Water-soluble / water-swellable polymers chemically include a lot
• hydrophilic groups can be nonionic, anionic, cationic and / or zwitterionic.
• the at least one cellulose derivative comprises in the
• the at least one cellulose derivative comprises a mixture of two cellulose derivatives having different viscosities, preferably a mixture of two hydroxypropylmethylcelluloses having different viscosities.
• the at least one cellulose derivative comprises a mixture of two cellulose derivatives having different viscosities, preferably a mixture of two hydroxypropylmethylcelluloses having different viscosities.
• oral thin film according to the invention a mixture of two
• the ratio of low-viscosity to higher-viscosity is preferred.
• Cellulose derivative preferably from low viscosity hydroxypropylmethylcellulose to higher viscosity hydroxypropylmethylcellulose, about 1: 5 to 5: 1.
• a mixture of a lower and a higher-viscosity cellulose derivative, preferably hydroxypropylmethylcellulose, has the advantage that the solids content and viscosity of the liquid mixture are acceptable for the preparation
• the oral thin film according to the invention is preferably characterized in that the at least one pharmaceutically active ingredient has a molecular weight of at most about 1000 g / mol, preferably of at most about 500 g / mol.
• ketamine is (S) - ( ⁇ ) -2- (2-chlorophenyl) -2- (methylamino) cyclohexan-1-one, (R) - ( ⁇ ) - 2- (2-chlorophenyl) -2- ( methylamino) cyclohexan-1-one, as well as the racemate (RS) - ( ⁇ ) - 2- (2-chlorophenyl) -2- (methylamino) cyclohexan-1-one understood.
• both (S) -ketamine and (R) -ketamine, as well as a racemic mixture of these two may be contained in the oral thin film of the present invention.
• (S) -ketamine or a pharmaceutically acceptable salt thereof, especially (S) -ketamine HCl is present as the sole stereoisomer of ketamine, since the analgesic and anesthetic potency of (S) -ketamine is about three times higher than that of (R) form is.
• the oral thin film according to the invention is preferably characterized in that the oral thin film comprises at least one adjuvant selected from the group comprising colorants, flavors, sweeteners, taste-masking agents, emulsifiers, enhancers, pH regulators, humectants, preservatives and / or antioxidants.
• Each of these adjuvants is preferably contained in an amount of about 0.1 to 10% by weight, based on the total weight of the oral thin film, in the oral thin film.
• the oral thin film according to the invention is preferably characterized in that the basis weight of the oral thin film is about 50 to 300 g / m 2 ,
• the oral thin film according to the invention comprises about 40 to 45 wt .-%, preferably about 41 wt .-%, (S) -Ketamin HCl, about 35 to 40% by weight, preferably about 39.5 wt .-% , a hydroxypropylmethylcellulose having a viscosity of about 1 to 5 mPas, preferably about 3 mPas, about 5 to 15 wt .-%, preferably about 10 wt .-%, one
• Hydroxypropylmethylcellulose having a viscosity of about 40 to 60 mPas, preferably of about 50 mPas, and the usual auxiliaries in an amount of about 0.1 to 10 wt .-%.
• Such an oral thin film preferably has a basis weight of about 175 g / m 2 .
• the oral thin film according to the invention is not a foam.
• the present invention further relates to a method for producing the above-described oral thin film.
• the method comprises the steps a) preparing an aqueous suspension or solution comprising the at least one cellulose derivative and the at least one pharmaceutically active substance; and b) stripping and drying the suspension obtained in step a) or
• Suspension or solution is dried about 50 ° C to 90 ° C, preferably about 60 ° C to 80 ° C and more preferably about 70 ° C.
• the at least one pharmaceutically active ingredient is particularly homogeneously distributed in the resulting oral thin film.
• the solvent can not be completely removed, on the other hand there is an inhomogeneous crystallization, with a very inhomogeneous line image, of the at least one pharmaceutically active substance, which is undesirable.
• the process of the invention is further characterized in that the at least one cellulose derivative preferably comprises hydroxypropylmethylcellulose.
• the present invention further relates to an oral thin film obtainable by the method described above.
• the present invention relates to an oral thin film as described above or obtainable by the method described above as a medicine.
• the present invention also relates to an oral thin film as described above or obtainable by the method described above as a medicament for use in the treatment of depression, in particular to reduce suicidal risk and / or for use as
• General anesthetic preferably for the initiation and performance of general anesthesia or as a supplement in regional anesthetics and / or as
• FIG. 1 shows a thin film according to the invention according to the formulation listed in Table 1 directly after the coating.
• Figure 2 shows a thin film according to the recipe listed in Table 1, which was dried at room temperature (about 20 ° C).
• Figure 3 shows a thin film according to the recipe listed in Table 1, which has been dried according to the invention at about 70 ° C.
• an oral thin film with the recipes listed in Table 1 was prepared in each case. Subsequently, the disintegration time of the oral thin films was measured by the USP method ⁇ 701> disintegration, from 2016.
• An oral thin film was prepared according to the inventive formulation from Table 1 according to the method of the invention and dried at 70 ° C.
• the same formulation was dried at room temperature (about 20 ° C).
• FIG. 1 shows the thin film according to the invention in accordance with the formulation listed in Table 1 directly after the coating.
• the active ingredient (S) -ketamine is partially dissolved or partially particulate.
• Figure 2 shows a thin film according to the recipe listed in Table 1, which was dried at room temperature (about 20 ° C).
• the active ingredient (S) -ketamine is inhomogeneously crystallized.
• Figure 3 shows a thin film according to the recipe listed in Table 1, which has been dried according to the invention at about 70 ° C.
• the active substance (S) -ketamine is extremely homogeneous.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Nutrition Science (AREA)
• Inorganic Chemistry (AREA)
• Physiology (AREA)
• Psychiatry (AREA)
• Biomedical Technology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Neurology (AREA)
• Pain & Pain Management (AREA)
• General Chemical & Material Sciences (AREA)
• Neurosurgery (AREA)
• Zoology (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=64746523

Family Applications (1)

Country Status (12)

Families Citing this family (8)

Family Cites Families (7)

• 2017
  • 2017-12-06 DE DE102017129012.5A patent/DE102017129012A1/de active Pending
• 2018
  • 2018-12-06 CN CN201880078745.6A patent/CN111447920A/zh active Pending
  • 2018-12-06 RU RU2020122136A patent/RU2754824C1/ru active
  • 2018-12-06 AU AU2018380864A patent/AU2018380864B2/en active Active
  • 2018-12-06 WO PCT/EP2018/083781 patent/WO2019110727A1/de active Search and Examination
  • 2018-12-06 JP JP2020530650A patent/JP7444775B2/ja active Active
  • 2018-12-06 EP EP18822284.8A patent/EP3720419A1/de active Pending
  • 2018-12-06 US US16/770,501 patent/US20200383936A1/en active Pending
  • 2018-12-06 MX MX2020005942A patent/MX2020005942A/es unknown
  • 2018-12-06 BR BR112020010175-3A patent/BR112020010175A2/pt active Search and Examination
  • 2018-12-06 CA CA3085020A patent/CA3085020C/en active Active
  • 2018-12-06 KR KR1020207019262A patent/KR102378847B1/ko active IP Right Grant

Also Published As

Similar Documents

Legal Events